cloudfront

Report Detail



Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview

              Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Assessment

                            Assessment by Mechanism of Action

                              Assessment by Route of Administration

                                Assessment by Molecule Type

                                  Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies Involved in Therapeutics Development

                                    3SBio Inc

                                      Bausch Health Companies Inc

                                        Lee's Pharmaceutical Holdings Ltd

                                          Phosphagenics Ltd

                                            Promius Pharma LLC

                                              Sol-Gel Technologies Ltd

                                                Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles

                                                  (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          (adapalene + clindamycin hydrochloride) - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  (benzoyl peroxide + tretinoin) - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          (benzoyl peroxide + tretinoin) - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  (clindamycin phosphate + tretinoin) - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          (halobetasol propionate + tazarotene) - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  (TPX-6001 + tretinoin) - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          AC-261066 - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  alitretinoin - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          KCL-286 - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  SBD-073 - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          tamibarotene - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  tazarotene - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          tazarotene - Drug Profile

                                                                                                                                                            Product Description

                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                R&D Progress

                                                                                                                                                                  tretinoin - Drug Profile

                                                                                                                                                                    Product Description

                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                        R&D Progress

                                                                                                                                                                          tretinoin - Drug Profile

                                                                                                                                                                            Product Description

                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                R&D Progress

                                                                                                                                                                                  tretinoin - Drug Profile

                                                                                                                                                                                    Product Description

                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                          vitamin A palmitate - Drug Profile

                                                                                                                                                                                            Product Description

                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                  vitamin A palmitate - Drug Profile

                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                          Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products

                                                                                                                                                                                                            Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products

                                                                                                                                                                                                              Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones

                                                                                                                                                                                                                Featured News & Press Releases

                                                                                                                                                                                                                  Jul 10, 2018: Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

                                                                                                                                                                                                                    Jun 18, 2018: FDA declines to approve Valeant’s plaque psoriasis lotion

                                                                                                                                                                                                                      Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion

                                                                                                                                                                                                                        Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology

                                                                                                                                                                                                                          Feb 15, 2018: Sol-Gel’s Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting

                                                                                                                                                                                                                            Jan 22, 2018: Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARa Agonist

                                                                                                                                                                                                                              Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

                                                                                                                                                                                                                                Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients

                                                                                                                                                                                                                                  Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients

                                                                                                                                                                                                                                    Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

                                                                                                                                                                                                                                      Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

                                                                                                                                                                                                                                        Nov 01, 2017: Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 At ASH Annual Meeting

                                                                                                                                                                                                                                          Oct 05, 2017: Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML

                                                                                                                                                                                                                                            Sep 29, 2017: Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML

                                                                                                                                                                                                                                              Sep 28, 2017: A novel RARb agonist for spinal cord injury receives funding for a phase 1 trial from the MRC-DPFS

                                                                                                                                                                                                                                                Appendix

                                                                                                                                                                                                                                                  Methodology

                                                                                                                                                                                                                                                    Coverage

                                                                                                                                                                                                                                                      Secondary Research

                                                                                                                                                                                                                                                        Primary Research

                                                                                                                                                                                                                                                          Expert Panel Validation

                                                                                                                                                                                                                                                            Contact Us

                                                                                                                                                                                                                                                              Disclaimer

                                                                                                                                                                                                                                                              Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

                                                                                                                                                                                                                                                              Summary

                                                                                                                                                                                                                                                              Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as anregulate activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions.

                                                                                                                                                                                                                                                              Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 6, 4 and 1 respectively.

                                                                                                                                                                                                                                                              Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Respiratory, Central Nervous System, Hematological Disorders, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Germ Cell Tumors, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Spinal Cord Injury, Traumatic Nerve Injury and Type 2 Diabetes.

                                                                                                                                                                                                                                                              The latest report Retinoic Acid Receptor Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects.

                                                                                                                                                                                                                                                              The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

                                                                                                                                                                                                                                                              Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                              Scope

                                                                                                                                                                                                                                                              - The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
                                                                                                                                                                                                                                                              - The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                                                                                                                                                                                              - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                                                                                                                                                                                              - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                                                                                                                                                                                              - The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects
                                                                                                                                                                                                                                                              - The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                                                                                                                                                                                              - The report summarizes all the dormant and discontinued pipeline projects
                                                                                                                                                                                                                                                              - The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics

                                                                                                                                                                                                                                                              Reasons to buy

                                                                                                                                                                                                                                                              - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                                                                                                                                                                                              - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                                                                                                                                                                                              - Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
                                                                                                                                                                                                                                                              - Identify the use of drugs for target identification and drug repurposing
                                                                                                                                                                                                                                                              - Identify potential new clients or partners in the target demographic
                                                                                                                                                                                                                                                              - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                                                                                                                                                                                              - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                                                                                                                                                                                              - Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape
                                                                                                                                                                                                                                                              - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




                                                                                                                                                                                                                                                              Summary:
                                                                                                                                                                                                                                                              Get latest Market Research Reports on Retinoic Acid Receptor Beta . Industry analysis & Market Report on Retinoic Acid Receptor Beta is a syndicated market report, published as Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Retinoic Acid Receptor Beta market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                                                                                                                                              REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                              Purchase this Report

                                                                                                                                                                                                                                                              $3,500.00
                                                                                                                                                                                                                                                              $7,000.00
                                                                                                                                                                                                                                                              $10,500.00
                                                                                                                                                                                                                                                              2,350.25
                                                                                                                                                                                                                                                              4,700.50
                                                                                                                                                                                                                                                              7,050.75
                                                                                                                                                                                                                                                              3,220.70
                                                                                                                                                                                                                                                              6,441.40
                                                                                                                                                                                                                                                              9,662.10
                                                                                                                                                                                                                                                              423,990.00
                                                                                                                                                                                                                                                              847,980.00
                                                                                                                                                                                                                                                              1,271,970.00
                                                                                                                                                                                                                                                              232,096.90
                                                                                                                                                                                                                                                              464,193.80
                                                                                                                                                                                                                                                              696,290.70
                                                                                                                                                                                                                                                              Add To Cart Credit card Logo

                                                                                                                                                                                                                                                              Related Reports


                                                                                                                                                                                                                                                              Reason to Buy

                                                                                                                                                                                                                                                              Request for Sample of this report